5-HTPvsOmega-3 (DHA)

5-HTP readily crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1/SLC7A5), unlike serotonin itself which cannot. Once in the brain, aromatic L-amino acid decarboxylase (AADC, also called DOPA decarboxylase) converts 5-HTP to serotonin (5-hydroxytryptamine) using pyridoxal-5-phosphate (active vitamin B6) as a cofactor. This completely bypasses tryptophan hydroxylase (TPH2), the rate-limiting enzyme in the normal serotonin synthesis pathway from dietary L-tryptophan. The result is a reliable, dose-dependent increase in serotonin across multiple brain regions including the dorsal raphe nucleus, hippocampus, and prefrontal cortex. Elevated serotonin activates 5-HT1A autoreceptors (calming), 5-HT2A/2C postsynaptic receptors (mood modulation), and 5-HT3 receptors (gut-brain signaling). In the pineal gland, serotonin is converted by arylalkylamine N-acetyltransferase (AANAT) to N-acetylserotonin, then by hydroxyindole O-methyltransferase (HIOMT) to melatonin — explaining the sleep-promoting effects.

DHA is a structural component of neuronal phospholipids (particularly phosphatidylethanolamine and phosphatidylserine in synaptic membranes), maintaining membrane fluidity which is essential for G-protein-coupled receptor function, ion channel gating, and synaptic vesicle fusion. DHA is metabolized by 15-lipoxygenase to specialized pro-resolving mediators (SPMs) including neuroprotectin D1 (NPD1), which actively resolve neuroinflammation by reducing NF-kappaB activation and pro-inflammatory cytokine production. DHA supports BDNF expression through modulation of the CREB pathway and promotes synaptic plasticity by enhancing long-term potentiation (LTP) and dendritic spine density. It also influences neurotransmitter receptor conformation and binding efficiency. Deficiency impairs membrane signaling, increases neuroinflammation, and accelerates cognitive decline.